单位：[1]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China[2]307 Hosp PLA, Beijing, Peoples R China[3]Guangzhou Nanfang Hosp, Guangzhou, Peoples R China[4]Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100037, Peoples R China[5]Shanghai First Peoples Hosp, Shanghai, Peoples R China[6]Beijing Canc Hosp, Beijing, Peoples R China[7]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan 430074, Peoples R China华中科技大学同济医学院附属同济医院[8]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China[9]Qingdao Univ, Affiliated Hosp Med Coll, Qingdao 266071, Peoples R China[10]Third Mil Med Univ Peoples Liberat Army, Affiliated Hosp 3, Chongqing, Peoples R China
第一作者单位：[1]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Guan Z.,Xu J.,Luo R.,et al.BEVACIZUMAB PLUS CHEMOTHERAPY IN CHINESE PATIENTS WITH METASTATIC COLORECTAL CANCER: EFFICACY AND TOLERABILITY RESULTS FROM THE ARTIST STUDY[J].ANNALS OF ONCOLOGY.2010,21:22-22.
APA：
Guan, Z.,Xu, J.,Luo, R.,Feng, F.,Wang, L....&He, J..(2010).BEVACIZUMAB PLUS CHEMOTHERAPY IN CHINESE PATIENTS WITH METASTATIC COLORECTAL CANCER: EFFICACY AND TOLERABILITY RESULTS FROM THE ARTIST STUDY.ANNALS OF ONCOLOGY,21,
MLA：
Guan, Z.,et al."BEVACIZUMAB PLUS CHEMOTHERAPY IN CHINESE PATIENTS WITH METASTATIC COLORECTAL CANCER: EFFICACY AND TOLERABILITY RESULTS FROM THE ARTIST STUDY".ANNALS OF ONCOLOGY 21.(2010):22-22
医学